CoChat

Therapeutic drug monitoring of β-lactam antibiotics in the critically ill: Direct measurement of unbound drug concentrations to achieve appropriate drug exposures.

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Abstract

Objectives: To describe the achievement of unbound β-lactam antibiotic concentration targets in a therapeutic drug monitoring (TDM) programme in critically ill patients, and the factors associated with failure to achieve a target concentration. Patients and methods: Plasma samples and clinical data were obtained for analysis from a single centre prospectively. Unbound concentrations of ceftriaxone, cefazolin, meropenem, ampicillin, benzylpenicillin, flucloxacillin and piperacillin were directly measured using ultracentrifugation. Factors associated with the achievement of pharmacokinetic/pharmacodynamic (PK/PD) targets or negative clinical outcomes were evaluated with binomial logistic regression. Results: TDM data from 330 patients, and 369 infection episodes, were included. The range of doses administered was 99.4% ± 45.1% relative to a standard daily dose. Dose increases were indicated in 33.1% and 63.4% of cases to achieve PK/PD targets of 100% fT>MIC and 100% fT>4×MIC, respectively. Dose reduction was indicated in 17.3% of cases for an upper PK/PD threshold of 100% fT>10×MIC. Higher protein bound β-lactams (ceftriaxone and benzylpenicillin) had better therapeutic target attainment (P < 0.01), but were prone to excessive dosing. Augmented renal clearance (calculated CLCR >130 mL/min) increased the odds of failure to achieve 100% fT>MIC and 100% fT>4×MIC (OR 2.47 and 3.05, respectively; P < 0.01). Conclusions: Measuring unbound concentrations of β-lactams as part of a routine TDM programme is feasible and demonstrates that a large number of critically ill patients do not achieve predefined PK/PD targets. The clinical significance of this finding is unknown due to the lack of correlation between PK/PD findings and clinical outcomes.

Overview

Integrity signals

Registry

Crossref · 10.1093/jac/dky314

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

See all 169

Metadata

Authors
Wong, G., Briscoe, S., McWhinney, B., Ally, M., Ungerer, J., Lipman, J., & Roberts, J. A.
Affiliations
  • The University of Queensland (AU)
  • Chemical Pathology, Pathology Queensland, Brisbane, Queensland, Australia
Corresponding author
Roberts, Jason A
Venue
Journal of Antimicrobial Chemotherapy
Published
2018-08-17
Volume
73
Issue
11
Pages
3087-3094
ISSN
  • 0305-7453 (ISSN-L)
  • 1460-2091
OpenAlex
W2887835365
Cited by
169
References
40
Citations by year
2026: 7 · 2025: 10 · 2024: 28 · 2023: 32 · 2022: 34 · 2021: 25 · 2020: 21 · 2019: 10 · 2018: 2
FWCI
9.35
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Antimicrobial Chemotherapy (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Health and Medical Research Council of Australia (APP1117065)
  • Australian National Health and Medical Research Council for Centre of Research Excellence (APP1099452)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
  • Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
  • Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
Keywords
beta-lactam antibiotics, therapeutic drug monitoring, unbound drug concentration, critically ill patients, PK/PD targets, ceftriaxone, cefazolin, meropenem, ampicillin, penicillin G, flucloxacillin, piperacillin, protein binding, renal clearance, dose adjustment, infection treatment
MeSH terms
Meropenem, Adult, Aged, Anti-Bacterial Agents, Ceftriaxone, Female, Humans, Male, Microbial Sensitivity Tests, Middle Aged, Piperacillin, Prospective Studies, Logistic Models, Critical Illness, Treatment Outcome, Drug Monitoring, beta-Lactams

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.